Impax Laboratories (IPXL) - FREE Research Report Markbreiter Michael who is Director at Impax Laboratories sold 4,000 shares at $27.54 on March 12, 2014. Following this transaction, the Director owned 9,699 shares meaning that the stake was reduced by 29.2% with the 4,000-share transaction. The shares most recently traded at $27.59, up $0.05, or 0.18% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:
4-Week # shares sold: 1,500
12-Week # shares sold: 1,500
24-Week # shares sold: 6,000
The average volume for Impax Laboratories has been 534,500 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 8.47% year-to-date as of the close of trading on Friday. Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 18.6. Currently there are 3 analysts that rate Impax Laboratories a buy, 2 analysts rate it a sell, and 5 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on IPXL - FREETheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and feeble growth in the company's earnings per share. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.